Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)

a technology of fibroblast growth factor and glycopegylation, which is applied in the direction of depsipeptides, peptide/protein ingredients, fungi, etc., can solve the problems of short half life and mutagenic properties of fgf-9, fgf-20, fgf-21, etc., and achieves cost-effective effects

Inactive Publication Date: 2008-07-24
89BIO LTD +1
View PDF99 Cites 81 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025]It has now been discovered that the controlled modification of Fibroblast Growth Factor with one or more modifying groups (e.g., non-glycosidic modifying groups) affords a novel FGF peptide conjugate with pharmacokinetic properties that are improved relative to the corresponding native (un-modified) FGF. Furthermore, cost effective methods for reliable and reproducible production of the FGF peptide conjugates of the invention have been discovered and developed.

Problems solved by technology

Unfortunately, the administration of therapeutic proteins such as FGF-9, FGF-18, FGF-20, and FGF-21 for the treatment of diseases and conditions can be complicated by, for example, short half life and mutagenic properties.
The chemical modification of peptides, frequently results in an undesirable loss of peptide activity, which is attributable to the non-selective nature of the chemistries utilized to modify the peptide.
Although the mutant glycosidases are useful for forming free oligosaccharides, it has yet to be demonstrated that such enzymes are capable of appending glycosyl donors onto glycosylated or non-glycosylated peptides, nor have these enzymes been used with unactivated glycosyl donors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
  • Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
  • Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0439]Exemplary regions on FGF-20 that are suited for the introduction of glycosylation sites by mutation are shown in Table 5, above. In all cases, the N-terminal Met may be present or absent on any FPGF mutant. The numbering of the amino acid residues is based on the initial unmodified sequence in which the left most residue, methionine, is numbered as position 1. To highlight how the mutant sequence differs in respect to the unmodified sequence, the numbering of unmodified amino acids as they appear in the sequences below remains unchanged following the modification. More than one of the described sequence modifications may be present in an FGF mutant of the present invention. Specifically, the preferred regions for introduction of mutations to create a glycosylation site(s) not present in the wild-type peptide are the nucleotide sequences that encode: amino acids 1-7 (REGION 1; SEQ ID NO:2), amino acids 20-42 (REGION 2; SEQ ID NO:3), amino acids 43-60 (REGION 3; SEQ ID NO:4), am...

example 2

[0449]A library of FGF-20 peptides each with one potential O-linked glycosylation site as disclosed in Example 1, is expressed in E. coli or by using in vitro translation methods. Protein is purified using either a heparin binding or IMAC capture method and tested by for in vitro biological activity. Those protein sequences that retain in vitro activity are tested as acceptors for GlycoPEGylation. GlycoPEGylated FGF-20's (40 kDa branched) are purified for further biological evaluation as outlined above.

example 3

[0450]Exemplary regions on FGF-21 that are suited for the introduction of glycosylation sites by mutation are shown in Table 7, above. In all cases, the N-terminal Met may be present or absent on any FGF mutant. The numbering of the amino acid residues is based on the initial unmodified sequence in which the left most residue, methionine, is numbered as position 1. To highlight how the mutant sequence differs in respect to the unmodified sequence, the numbering of unmodified amino acids as they appear in the mutant sequences below remains unchanged following the modification. More than one of the described sequence modifications may be present in an FGF mutant of the present invention. Specifically, the preferred regions for introduction of mutations to create a glycosylation site(s) not present in the wild-type peptide are the nucleotide sequences that encode: amino acids 1-8 (REGION 1; SEQ ID NO:147), amino acids 9-13 (REGION 2; SEQ ID NO:148), amino acids 46-54 (REGION 3; SEQ ID ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular massaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application is related to U.S. Provisional Patent Application 60 / 623,342, filed Oct. 29, 2004, which is incorporated by reference in its entirety for all purposes.BACKGROUND OF THE INVENTION[0002]Fibroblast Growth Factors (FGFs) promote growth, proliferation, survival and differentiation of a wide variety of cells and tissue types. The prototypic fibroblast growth factors (FGFs), FGF-1 and FGF-2, were originally isolated from brain and pituitary as mitogens for fibroblasts. However, FGF-1 and FGF-2, and fibroblast growth factors generally, are widely expressed in developing and adult tissues, and have multiple biological activities including angiogenesis, mitogenesis, cellular differentiation and repair of tissue injury (see e.g., Baird, A. et al., Cancer Cells 3:239-243 (1991) and Burgess, W. H. et al., Annu. Rev. Biochem. 58:575-606 (1989)).[0003]According to the published literature, the FGF family now consists of at least ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/18C07K7/04C07K14/50C12N15/12C12N15/63A61P43/00C12N5/10C12N1/21C12N1/19C12P21/00
CPCC07K14/50A61K38/00A61K47/60A61K47/549A61K38/1825A61P1/04A61P17/00A61P17/02A61P19/04A61P19/08A61P21/00A61P25/00A61P25/16A61P27/02A61P29/00A61P35/00A61P43/00A61P9/10A61P3/10C12P21/005
Inventor DEFREES, SHAWN
Owner 89BIO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap